Login to Your Account



Puma's Nerlynx approved as extended adjuvant breast cancer therapy

By Jennifer Boggs
Managing Editor

Tuesday, July 18, 2017

Despite some skepticism heading toward the July 21 PDUFA date, Puma Biotechnology Inc.'s breast cancer drug, Nerlynx (neratinib), won FDA approval a few days early, marking the first treatment designated as an extended adjuvant therapy in patients with early stage, HER2-positive disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription